[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353347-105":59,"doc-detail-353347-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tp53-mutation-at-codon-179-metabolically-reprograms-cancer-cells-to-promote-invasion","TP53 mutation at codon 179 metabolically reprograms cancer cells to promote invasion","","Mutations in the tumour suppressor TP53 are common in human cancers, but their functional consequences have been unclear. A pan-cancer database analysis identified TP53 H179 mutations as linked to poorer disease-free survival across multiple tumour types. Functional assays in lung, ovarian and prostate cancer cells overexpressing p53 H179R/Y showed loss of tumour-suppressive activity alongside active promotion of progression via metabolic reprogramming, lipid accumulation and increased invasiveness. The findings show H179 missense variants act as oncogenic drivers rather than equivalent to TP53 loss, highlighting APOE and lipid metabolism as therapeutic targets.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tp53-mutation-at-codon-179-metabolically-reprograms-cancer-cells-to-promote-invasion/353347/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tp53-mutation-at-codon-179-metabolically-reprograms-cancer-cells-to-promote-invasion/353347.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What did the pan-cancer analysis reveal about TP53 H179 mutations?","Question",{"text":112,"@type":113},"H179 mutations in TP53 were significantly associated with poor disease-free survival across multiple cancer types.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do TP53 H179R/Y mutants affect cancer cell behavior in experiments?",{"text":117,"@type":113},"They are defective in tumour-suppressive functions and actively promote tumour progression and invasiveness compared with p53-null cells.",{"name":119,"@type":110,"acceptedAnswer":120},"Which metabolic changes are linked to H179-driven invasiveness?",{"text":121,"@type":113},"H179 mutants promote metabolic reprogramming by increasing neutral lipid levels through de novo fatty acid synthesis and fatty acid uptake, with more lipid droplets and increased APOE expression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353347,1790369407,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Cancer Gene [Therapy](Therapy www.nature.com/cgt)[ www.nature.com/cgt](Therapy www.nature.com/cgt)  \nARTICLE OPEN   \nTP53 mutation at codon 179 metabolically reprograms cancer cells to promote invasion  \nDebina Sarkar 1,2,9, Gaurav C. Gyanwali 1,2,9, Jaishree Patel1, Polina Shevchuk 1,2, Aaron Jeffs1, Adele G. Woolley 1,2, Selena Wang 1,2, Maryam Sardari 1,2, Apeksha Bhandarkar1,2, Halima Siddiqui2,3, Magdalena Ratajska1,2,4, Makhdoom Sarwar2,5, Srinivasaraghavan Kannan 6, Chandra S. Verma6,7,8, Catherine J. Drummond1,2, Cushla McKinney 1, Jisha Antony1, Sally P. McCormick2,3, Antony Braithwaite 1,2 and Sunali Mehta 1,2 ✉  \n© The Author(s) 2026  \n|  |  |  |\n| --- | --- | --- |\n|  | Mutations in the tumour suppressor, TP53, are prevalent in human cancers yet their functional implications remain unclear. Through comprehensive pan-cancer database analysis, we identiﬁed H179 mutations in TP53 as signiﬁcantly associated with poor diseasefree survival across multiple cancer types. Functional studies in lung, ovarian, and prostate cancer cells over-expressing thep53H179R/Y mutants revealed that these mutants are not only defective in tumour-suppressive functions but also actively promote tumour progression. These mutants drive metabolic reprogramming by increasing neutral lipid levels through de novo fatty acid synthesis (p53H179R/Y) and fatty acid uptake (p53H179Y), accompanied by increased lipid droplets and APOE expression, collectively promoting enhanced invasiveness relative to p53-null cells. Our ﬁndings demonstrate that TP53 missense mutations are not functionally equivalent to TP53 loss. Notably, H179 mutations act as oncogenic drivers, and our data highlight APOE and lipid |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| metabolism as potential therapeutic targets, underscoring the clinical relevance of precise TP53 mutation characterisation. |  |  |\n|  | Cancer Gene Therapy (2026) 33:775–794; [https://doi.org/10.1038/s41417-026-01045-4](https://doi.org/10.1038/s41417-026-01045-4) |  |\n|  |  |  |\n\nINTRODUCTION  \nThe p53 tumour suppressor protein is a transcription factor that plays a central role in maintaining the integrity of the genome by promoting repair, senescence, or apoptosis of DNA-damaged cells [1] . Loss of p53 function is often a precursor for tumour initiation and progression, which has been demonstrated by increased cancer risk in Li-Fraumeni syndrome patients with germline pathogenic variants, and p53 knockout mouse models [2, 3] . Unlike other tumour suppressor genes where loss of function occurs due to loss of heterozygosity, frameshift, or nonsense mutations, the majority of pathogenic TP53 mutations (~65%) are single nucleotide missense variants (Supplementary Fig. 1A) . Missense mutations at codons 175, 220, 245, 248, 249, 273, and 282 occur at a higher-than-expected frequency and are referred to as hotspots; however, they constitute of only one-third of reported missense p53 mutations [4] . Numerous studies have deepened our understanding of the structure and function of p53, yet they have not resulted in clinical applications. Lack of clinical utility can be attributed to the fact that not all p53 mutations are the same in terms of how they affect patient outcomes, p53 function, biological pathways, and response to therapy [5–11] . This is further compounded by the fact that there is little evidence on how the remaining two-thirds of the reported missense p53 mutations inﬂuence p53 function, biological processes, and, in turn, response to therapy and patient outcome. Emerging  \nevidence shows that mutant p53 not only disrupts tumoursuppressive functions but actively promotes oncogenic metabolic reprogramming by enhancing glycolysis through upregulation of GLUT1 and HK2 [12], stimulating lipid synthesis via SREBP activation [13], and inducing redox imbalance through altered NADPH and glutathione metabolism [14–16] . These changes fuel tumour progression and c","cbCaioiJAjAqAxFv","https://ap.wps.com/l/cbCaioiJAjAqAxFv","pdf",7286969,"English","# Introduction","[{\"question\":\"What did the pan-cancer analysis reveal about TP53 H179 mutations?\",\"answer\":\"H179 mutations in TP53 were significantly associated with poor disease-free survival across multiple cancer types.\"},{\"question\":\"How do TP53 H179R/Y mutants affect cancer cell behavior in experiments?\",\"answer\":\"They are defective in tumour-suppressive functions and actively promote tumour progression and invasiveness compared with p53-null cells.\"},{\"question\":\"Which metabolic changes are linked to H179-driven invasiveness?\",\"answer\":\"H179 mutants promote metabolic reprogramming by increasing neutral lipid levels through de novo fatty acid synthesis and fatty acid uptake, with more lipid droplets and increased APOE expression.\"}]","TP53 mutation at codon 179 metabolically reprograms cancer cells to promote invasion | PDF",1790104827,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56dfccc4eed1c0af5e08f5fb95d191e1.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff3dcdd30c542cc5afef594ce37f4097.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1dc6b863a04e804ae07694d527d43659.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0371c1b93f3a57400da17620a808290.webp",980,1301]